{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:11:05Z","timestamp":1793880665968,"version":"4.7.0"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"16","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA240592"],"award-info":[{"award-number":["R01CA240592"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Precision medicine in cancer care is predicated on access to several fundamental pieces of data: (i) a precise tumor diagnosis, (ii) accurate stage classification, and (iii) protein or molecular biomarkers that predict efficacy of targeted therapies. For all patients with cancer, these data points are generated by obtaining a tumor sample and subjecting it to analysis by a pathologist and, when appropriate, a molecular pathologist. While tumor diagnosis and pathologic staging (gross and microscopic examination of the primary tumor and draining lymph nodes) require the infrastructure and expertise of an anatomic pathology program, the advent of \u201cliquid biopsy\u201d has driven a shift in molecular biomarker testing away from local pathology laboratories and into high-throughput, centralized (and often for-profit) laboratories. What does this mean for patient care? How is the role of the pathologist affected? What are the implications for integration of diagnostic information and ultimately for appropriate therapy selection? This article will consider the current testing landscape, address current challenges in the use of liquid biopsy in clinical practice, and consider ways the pathologist should be involved in interpreting liquid biopsy data in the context of the patient's cancer diagnosis and stage.<\/jats:p>","DOI":"10.1158\/0008-5472.can-20-0134","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T21:42:30Z","timestamp":1593553350000},"page":"3197-3199","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy"],"prefix":"10.1158","volume":"80","author":[{"given":"Lynette M.","family":"Sholl","sequence":"first","affiliation":[{"name":"1Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Oxnard","sequence":"additional","affiliation":[{"name":"2Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cloud P.","family":"Paweletz","sequence":"additional","affiliation":[{"name":"3Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"2022061706322866800_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non\u2013small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"key":"2022061706322866800_bib2","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Onc"},{"key":"2022061706322866800_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00191","article-title":"Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance","volume":"3","author":"Stetson","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2022061706322866800_bib4","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"key":"2022061706322866800_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","article-title":"Germline variants in targeted tumor sequencing using matched normal DNA","volume":"2","author":"Schrader","year":"2016","journal-title":"JAMA Oncol"},{"key":"2022061706322866800_bib6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.4251","article-title":"Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary","volume":"231","author":"Tothill","year":"2013","journal-title":"J Pathol"},{"key":"2022061706322866800_bib7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"2022061706322866800_bib8","doi-asserted-by":"crossref","first-page":"eaat4921","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Trans Med"},{"key":"2022061706322866800_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3389\/fgene.2019.00789","article-title":"Preparing medical specialists to practice genomic medicine: education an essential part of a broader strategy","volume":"10","author":"Crellin","year":"2019","journal-title":"Front Genet"},{"key":"2022061706322866800_bib10","doi-asserted-by":"crossref","first-page":"e000469","DOI":"10.1136\/esmoopen-2018-000469","article-title":"Prospective analysis of 895 patients on a UK genomics review board","volume":"4","author":"Moore","year":"2019","journal-title":"ESMO Open"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/16\/3197\/2792190\/3197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/16\/3197\/2792190\/3197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T23:02:24Z","timestamp":1723158144000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/80\/16\/3197\/641096\/Traditional-Diagnostics-versus-Disruptive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":10,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2020,8,14]]},"published-print":{"date-parts":[[2020,8,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-20-0134","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]}}}